Posts by: Inacio Patricia

Inacio Patricia

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

December 1, 2020December 1, 2020

BioInvent to Produce CAN10, Cantargia’s Antibody for Scleroderma, Under New Deal

News

Cantargia‘s antibody CAN10, intended to treat people with scleroderma and myocarditis, will be produced by BioInvent under the terms of a new manufacturing agreement, the two companies announced. The investigational therapy is ... Read more

November 24, 2020November 24, 2020

Proteins Linked to Scarring, Immune Cell Activation Found at High Levels in dcSSc

News

Proteins involved in scarring and the escape of immune cells from blood vessels towards nearby tissues are found at high levels in people with diffuse cutaneous systemic sclerosis (dcSSc), ... Read more

November 5, 2020November 5, 2020

Galectin-3 Protein May Be Blood Biomarker for Scleroderma and Like Diseases

News

Elevated blood levels of a protein called galectin-3 can help diagnose people with rheumatic diseases that include scleroderma, rheumatoid arthritis, and systemic lupus erythematosus, a study suggests. The study, “Diagnostic ... Read more

October 29, 2020October 29, 2020

High Levels of S100A12 Protein May Increase Severity of Scarring, ILD, Study Suggests

News

Elevated blood levels of the S100A12 protein, a type of danger signal released by skin cells, may contribute to skin scarring and interstitial lung disease (ILD) in people with ... Read more

October 22, 2020October 22, 2020

Machine Learning Helps Predict Stem Cell Transplant Outcomes, Study Suggests

News

Using a computer-based analysis to profile gene activity in blood samples may help identify the severe scleroderma patients who are most likely to respond to a stem cell transplant, ... Read more

October 8, 2020October 8, 2020

AURORA Trial of CIVI030 for Raynaud’s Due to Scleroderma Resumes Patient Enrollment

News

A Phase 3 trial testing iloprost, known as CIVI030, for the treatment of Raynaud’s phenomenon due to scleroderma has resumed patient enrollment, according to the therapy’s developer, CiVi Biopharma. ... Read more

October 1, 2020October 1, 2020

Capillary.io Software Aims to Make Diagnosing Scleroderma Easier, Faster

News

A new computer software, called Capillary.io, uses artificial intelligence (AI) to aid in diagnosing scleroderma at early disease stages. The tool, developed in partnership with the Sociedad Española de Medicina Interna (SEMI), was designed ... Read more

September 22, 2020September 22, 2020

Scleroderma More Severe in People With Muscle Involvement, Study Finds

News

Muscular involvement is linked with more severe symptoms in people with scleroderma, affecting heart, lungs and the digestive system, a study from China reports. These patients are likely to have ... Read more

September 9, 2020September 9, 2020

Lenabasum Fails to Show Efficacy in Diffuse Cutaneous SSc, Phase 3 Trial Shows

News

Treatment with lenabasum failed to outperform a placebo when given as an add-on to standard immunosuppressants in adults with diffuse cutaneous scleroderma (dcSSc), top-line data from a Phase 3 ... Read more

August 31, 2020August 31, 2020

Phase 2 Trial of CellCept Plus Esbriet for SSc-ILD Enrolling in US

News

The Scleroderma Lung Study III (SLSIII), a Phase 2 clinical trial of oral CellCept (mycophenolate mofetil) alone or in combination with Esbriet (pirfenidone) in scleroderma-associated interstitial lung disease (ILD) is enrolling patients. The trial ... Read more